UBS analyst Brian Meredith raised the firm’s price target on Allstate to $160 from $150 and keeps a Buy rating on the shares as part of a broader research note on Insurance names. The analyst states that he favors commercial lines insurers going into Q4 earnings seasons as reinsurer valuations reflect favorable fundamentals.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALL:
- Allstate price target raised to $153 from $147 at Piper Sandler
- Allstate announces zero net emissions commitment by 2030
- Allstate implements auto insurance rates for November
- Allstate replacing Accenture’s Droga5 for creative account, AdAge reports
- Allstate names Christine DeBiase chief legal officer
